Cancer Test Firm NeoGenomics Reports Q1 Revenues up 3 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer genetic testing firm NeoGenomics today said that its revenues for the first quarter bounced 3 percent year over year.

Revenues for the three months ending March 31 totaled $15.7 million, compared to $15.2 million a year ago, as the number of requisitions in the quarter increased to 20,604 from 16,934 a year ago, and the number of tests performed climbed to 32,088 from 26,932.

Net income was down, however, to $3,000, or breakeven on a per-share basis, compared to a profit of $603,000, or $.01 per share, a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.